Kinovate Life Sciences Ribbon Cutting Ceremony
2025/10/10
On October 6, Deputy Consul General Kamitani participated in the ribbon cutting ceremony for the completion of the new manufacturing facility of Kinovate Life Sciences in Carlsbad, San Diego County.
Kinovate Life Sciences is a medical subsidiary under the Nitto Denko Corporation, and is engaged in the nucleic acid therapeutics business. The company processes polymer beads for nucleic acid synthesis imported from their group company in Japan. A new plant was built in Carlsbad in 2025 to expand its production capacity.
At the ceremony, the company representatives highlighted that the new facility is expected to enhance production capacity, further improve product quality, and strengthen efforts related to sustainability initiatives.
Deputy Consul General Kamitani mentioned in her remarks that nucleic acid therapeutics is an emerging technology with great promise for treating diseases once considered untreatable, and the number of approvals for commercialization is increasing year by year. She also noted the outstanding concentration of research infrastructure and talent in San Diego and hoped that Kinovate Life Sciences would continue to grow in the region.
Following the remarks, representatives from the pharmaceutical company and the construction company involved in building the facility also gave speeches. The ceremony concluded with a ribbon-cutting ceremony attended by senior executives of the Nitto Denko Corporation and distinguished guests.
Kinovate Life Sciences is a medical subsidiary under the Nitto Denko Corporation, and is engaged in the nucleic acid therapeutics business. The company processes polymer beads for nucleic acid synthesis imported from their group company in Japan. A new plant was built in Carlsbad in 2025 to expand its production capacity.
At the ceremony, the company representatives highlighted that the new facility is expected to enhance production capacity, further improve product quality, and strengthen efforts related to sustainability initiatives.
Deputy Consul General Kamitani mentioned in her remarks that nucleic acid therapeutics is an emerging technology with great promise for treating diseases once considered untreatable, and the number of approvals for commercialization is increasing year by year. She also noted the outstanding concentration of research infrastructure and talent in San Diego and hoped that Kinovate Life Sciences would continue to grow in the region.
Following the remarks, representatives from the pharmaceutical company and the construction company involved in building the facility also gave speeches. The ceremony concluded with a ribbon-cutting ceremony attended by senior executives of the Nitto Denko Corporation and distinguished guests.
 |
 |
| Remarks by President Shimizu of Kinovate Life Sciences | Remarks by Deputy Consul General Kamitani |
 |
|
| Ribbon Cutting Ceremony | |